Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy

Third-generation tyrosine kinase inhibitors (TKIs), such as osimertinib, almonertinib and furmonertinib, overcome the mechanisms of resistance to first-generation inhibitors (such as gefitinib, erlotinib and icotinib) by incorporating an acrylamide group that alkylates the Cys797 of EGFR T790M. Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Guoqing, Yan, Beibei, Guo, Yanan, Yang, Hang, Li, Xiangnan, Li, Jindong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659857/
https://www.ncbi.nlm.nih.gov/pubmed/36387265
http://dx.doi.org/10.3389/fonc.2022.995624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659857/
https://www.ncbi.nlm.nih.gov/pubmed/36387265
http://dx.doi.org/10.3389/fonc.2022.995624

Ejemplares similares